Top

Published in:

01-09-2017 | Correspondence

Does Metabolic Syndrome and Not the Inflammatory Load Predict Nonalcoholic Fatty Liver Disease Severity in Inflammatory Bowel Disease Patients?

Authors: Alessandro Sartini, Stefano Gitto, Erica Villa

Published in: Digestive Diseases and Sciences | Issue 9/2017

Excerpt

We read with great interest the paper by Carr et al. [1] on the role of metabolic syndrome (MetS) and intestinal inflammation in the severity of nonalcoholic fatty liver disease (NAFLD) in patients with inflammatory bowel disease (IBD). They intercepted IBD patients with established NAFLD by using ICD-9 codes, finding that the majority of IBD patients (77%) had NAFLD in the absence of MetS, obesity, diabetes, and/or insulin resistance, but the presence of MetS predicted NAFLD severity. This suggests that IBD patients could develop NAFLD and fibrosis not only because of metabolic risk factors. …

Carr RM, Patel A, Bownik H, et al. Intestinal inflammation does not predict nonalcoholic fatty liver disease severity in inflammatory bowel disease patients. Dig Dis Sci. 2017;5:1354–1361. doi:10.1007/s10620-017-4495-0.CrossRef

Colombel JF, Sandborn WJ, Reinisch W, et al. Infliximab, azathioprine, or combination therapy for Crohn’s disease. N Engl J Med. 2010;15:1383–1395.CrossRef

Woods CP, Hazlehurst JM, Tomlinson JW. Glucocorticoids and nonalcoholic fatty liver disease. J Steroid Biochem Mol Biol. 2015;154:94–103.CrossRefPubMed

Bessissow T, Le NH, Rollet K, Afif W, Bitton A, Sebastiani G. Incidence and predictors of nonalcoholic fatty liver disease by serum biomarkers in patients with inflammatory bowel disease. Inflamm Bowel Dis. 2016;8:1937–1944.CrossRef

Brahmania M, Bernstein CN. Physician global assessments or blood tests do not predict mucosal healing in ulcerative colitis. Can J Gastroenterol Hepatol. 2014;6:325–329.CrossRef

Sipponen T, Kolho K-L. Fecal calprotectin in diagnosis and clinical assessment of inflammatory bowel disease. Scand J Gastroenterol. 2015;1:74–80.CrossRef

Silverberg MS, Satsangi J, Ahmad T, et al. Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a Working Party of the 2005 Montreal World Congress of Gastroenterology. Can J Gastroenterol. 2005;19:5A–36A.CrossRefPubMed

Lichtenstein GR, Hanauer SB, Sandborn WJ. Practice parameters Committee of American College of G. Management of Crohn’s disease in adults. Am J Gastroenterol. 2009;104:465–483.CrossRefPubMed

Caliendo M, Kopeinig S. Some practical guidance for the implementation of propensity score matching. J Econ Surv. 2008;22:31–72.CrossRef

10.

Thirumurthi S, Chowdhury R, Richardson P, Abraham NS. Validation of ICD-9-CM diagnostic codes for inflammatory bowel disease among veterans. Dig Dis Sci. 2010;55:2592–2598. doi:10.1007/s10620-009-1074-z.CrossRefPubMed

11.

Kramer JR, Davila JA, Miller ED, Richardson P, Giordano TP, El-Serag HB. The validity of viral hepatitis and chronic liver disease diagnoses in Veterans Affairs administrative databases. Aliment Pharmacol Ther. 2008;27:274–282.CrossRefPubMed

12.

Kim D, Kim W, Kim HJ, Therneau TM. Association between noninvasive fibrosis markers and mortality among adults with nonalcoholic fatty liver disease in the United States. Hepatology. 2013;57:1357–1365.CrossRefPubMedPubMedCentral

Title: Does Metabolic Syndrome and Not the Inflammatory Load Predict Nonalcoholic Fatty Liver Disease Severity in Inflammatory Bowel Disease Patients?
Authors: Alessandro Sartini
Stefano Gitto
Erica Villa
Publication date: 01-09-2017
Publisher: Springer US
Published in: Digestive Diseases and Sciences / Issue 9/2017
Print ISSN: 0163-2116
Electronic ISSN: 1573-2568
DOI: https://doi.org/10.1007/s10620-017-4665-0

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Does Metabolic Syndrome and Not the Inflammatory Load Predict Nonalcoholic Fatty Liver Disease Severity in Inflammatory Bowel Disease Patients?

Excerpt

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 9/2017

Crossover Subsets of CD4+ T Lymphocytes in the Intestinal Lamina Propria of Patients with Crohn’s Disease and Ulcerative Colitis

Is There a Link Between H. Pylori and the Epidemiology of Crohn’s Disease?

Global Disparities and Their Implications in the Occurrence and Outcome of Autoimmune Hepatitis

Latiglutenase Improves Symptoms in Seropositive Celiac Disease Patients While on a Gluten-Free Diet

CD4 T Cells in IBD: Crossing the Line?

CHD1L Expression Increases Tumor Progression and Acts as a Predictive Biomarker for Poor Prognosis in Pancreatic Cancer

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page